Results 21 to 30 of about 9,982 (193)

Case Report: Exacerbation after fat grafting in patients with active localized scleroderma [PDF]

open access: yesFrontiers in Surgery
BackgroundThe application of autologous fat transplantation in facial lesions of patients with localized scleroderma (LoS) has been reported in recent years.ObjectiveThe authors report a case of worsening of active localized scleroderma after autologous ...
Shunxin Han   +3 more
doaj   +2 more sources

Intramuscular Polydeoxyribonucleotides in Fibrotic and Atrophic Localized Scleroderma: An Explorative Prospective Cohort Study [PDF]

open access: yesBiomedicines, 2023
Effective options in the quiescent, scantily inflammatory phase of localized scleroderma (morphea) are lacking. A cohort study in patients with histologically confirmed fibroatrophic morphea explored the therapeutic value of the anti-dystrophic A2A ...
Maurizio Romagnuolo   +5 more
doaj   +2 more sources

Modern methods of a localized scleroderma diagnostics [PDF]

open access: yesСаратовский научно-медицинский журнал, 2016
Localized scleroderma (LS) is a disease that is characterized by the appearance of inflammatory, sclerotic and/or atrophic changes in the affected areas of the skin and underlying tissues.
Moiseyev А.А., Utz S.R.
doaj   +1 more source

Successful treatment of localized scleroderma using brodalumab: A case report [PDF]

open access: yesSAGE Open Medical Case Reports
We report the first documented use of brodalumab, an IL-17 receptor antagonist, for treating severe linear localized scleroderma refractory to conventional therapies, including methotrexate, mycophenolate mofetil and corticosteroids.
Alexandra Carla Bobica   +4 more
doaj   +2 more sources

Histological Changes of Linear Scleroderma “en Coup de Sabre”

open access: yesЛьвівський клінічний вісник, 2014
Introduction. Scleroderma is a chronic disease of unknown aetiology characterized by skin fibrosis and is divided into two clinical entities: localized scleroderma and systemic sclerosis.
Matoshvili M.   +3 more
doaj   +2 more sources

Localized scleroderma secondary to mixed connective tissue disease during abatacept therapy

open access: yesJournal of Cutaneous Immunology and Allergy, 2022
A 47‐year‐old woman with mixed connective tissue disease was treated with abatacept. After 2 months, a 3‐cm depression with atrophied surface was observed on her back, which had histopathological consistent with the symptoms of localized scleroderma ...
Sayuko Nagaoka   +2 more
doaj   +2 more sources

The role of Borrelia burgdorferi infection in scleroderma

open access: yesRheumatology, 2014
Borrelia burgdorferi , a Gram-negative, spiral-shaped bacterium transmitted to humans via tick bites, is the etiologic agent of borreliosis (Lyme disease) with diverse clinical manifestations. There are several types of pathological lesions in the course
Żaneta Smoleńska   +3 more
doaj   +2 more sources

Evaluation of mean platelet volume in localized scleroderma [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2017
: Background: Localized scleroderma is a chronic inflammatory skin disease characterized by sclerosis of the dermis and subcutaneous tissue. Platelets play an important role in inflammation.
Anil Gulsel Bahali   +5 more
doaj   +2 more sources

Chronic venous insufficiency – a potential trigger for localized scleroderma

open access: yesJournal of the European Academy of Dermatology and Venereology, 2006
Localized scleroderma is a cutaneous disease that is characterized by an initial inflammatory response, followed by sclerosis of the skin. The cause of localized scleroderma has not yet been determined. Seifarth et al.
Ralf J Ludwig
exaly   +2 more sources

Localized scleroderma in a newborn (case report) [PDF]

open access: yesРМЖ. Мать и дитя, 2022
N.I. Akhmina1, P.S. Utkin2, M.P. Shalatonin3, Zh.L. Chabaidze1, A.A. Dement’ev1, A.L. Zaplatnikov1 1Russian Medical Academy of Continuous Professional Education, Moscow,   Russian Federation 2Children’s Infectious Clinical Hospital
N.I. Akhmina   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy